Blockade of HERG human K+channels by the antidepressant drug paroxetine

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 9, 2014, Pages 1495-1505

  Lee, Seung Ho ^a   Sung, Min Ji ^a   Lee, Hyang Mi ^a   Chu, Daehyun ^b   Hahn, Sang June ^b   Jo, Su Hyun ^c   Choe, Han ^b   Choi, Bok Hee ^a  

^a Chonbuk National University Medical School   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kangwon National University College of Medicine   (South Korea)

Author keywords

Antidepressant; Human ether a go go related gene channel; Paroxetine; Rapidly activating delayed rectifier K+channel

Indexed keywords

PAROXETINE; POTASSIUM CHANNEL HERG; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ELECTROPHYSIOLOGY; HEK293 CELL LINE; HILL COEFFICIENT; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; MEMBRANE POTENTIAL; MOLECULAR DOCKING; PHARMACOLOGICAL BLOCKING; STEADY STATE; WHOLE CELL PATCH CLAMP; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; ION CHANNEL GATING; MODELS, MOLECULAR; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84906957428     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00244     Document Type: Article

References (41)

1. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ, 310, 221-224 (1995).
2. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf., 16, 374-390 (1997).
3. Reilly JG, Ayis SA, Ferrier I.N., Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048-1052 (2000).
4. Scherer D, von Löwenstern K, Zitron E, Scholz EP, Bloehs R, Kathöfer S, Thomas D, Bauer A, Katus HA, Karle CA, Kiesecker C. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch. Pharmacol., 378, 73-83 (2008).
5. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuropsy-chopharmacol. Biol. Psychiatry, 6, 277-295 (1982).
6. Wong DT, Bymaster FP, Engleman EA. Prozac (fuoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antide-pressant drug: twenty years since its first publication. Life Sci., 57, 411-441 (1995).
7. Anderson IM. Selective serotonin reuptake inhibitors versus tricy-clic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord., 58, 19-36 (2000).
8. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int. Clin. Psychopharmacol., 16, 169-178 (2001).
9. +currents by antidepressant sertraline and paroxetine. J. Membr. Biol., 222, 79-90 (2008).
10. Dick IE, Brochu RM, Purohit Y, Kaczorowski G.J., Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J. Pain, 8, 315-324 (2007).
11. Huang CJ, Harootunian A, Maher M.P., Quan C., Raj CD, McCor-mack K, Numann R, Negulescu P.A., Gonzalez JE. Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fuorescence detection of membrane potential. Nat. Biotechnol., 24, 439-446 (2006).
12. +channels by the antidepressant paroxetine. J. Pharmacol. Sci., 102, 278-287 (2006).
13. Thümmler S, Duprat F, Lazdunski M. Antipsychotics inhibit TREK but not TRAAK channels. Biochem. Biophys. Res. Commun., 354, 284-289 (2007).
14. +current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195-215 (1990).
15. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92-95 (1995).
16. Curran ME, Splawski I, Timothy K.W., Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 80, 795-803 (1995).
17. Viskin S. Long QT syndromes and torsade de pointes. Lancet, 354, 1625-1633 (1999).
18. Suessbrich H, Waldegger S, Lang F., Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett., 385, 77-80 (1996).
19. +channels as pharmacological targets: present and future implications. Biochem. Pharmacol., 55, 1741-1746 (1998).
20. Suessbrich H, Schonherr R, Heinemann S.H., Attali B., Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperi-dol on HERG potassium channels expressed in Xenopus oocytes. Br. J. Pharmacol., 120, 968-974 (1997).
21. Zhou Z, Gong Q, Ye B., Fan Z, Makielski JC, Robertson G.A., January CT. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J., 74, 230-241 (1998).
22. Hamill OP, Marty A, Neher E., Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch., 391, 85-100 (1981).
23. Woodhull AM. Ionic blockage of sodium channels in nerve. J. Gen. Physiol., 61, 687-708 (1973).
24. Sanguinetti MC, Chen J, Fernandez D., Kamiya K, Mitcheson J, Sanchez-Chapula JA. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs. Novartis Found. Symp., 266, 159-166, discussion, 166-170 (2005).
25. Choe H, Nah KH, Lee S.N., Lee HS, Lee HS, Jo SH, Leem C.H., Jang YJ. A novel hypothesis for the binding mode of HERG channel blockers. Biochem. Biophys. Res. Commun., 344, 72-78 (2006).
26. Kiehn J, Lacerda AE, Brown AM. Pathways of HERG inactivation. Am. J. Physiol., 277, H199-H210 (1999).
27. Scholz EP, Zitron E, Kiesecker C., Lück S, Thomas D., Kathöfer S, Kreye VA, Katus HA, Kiehn J, Schoels W, Karle CA. Inhibition of cardiac HERG channels by grapefruit favonoid naringenin: implications for the infuence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch. Pharmacol., 371, 516-525 (2005).
28. Scholz EP, Zitron E, Kiesecker C., Lueck S, Kathöfer S, Thomas D., Weretka S, Peth S, Kreye VAW, Schoels W, Katus HA, Kiehn J, Karle CA. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch. Pharmacol., 368, 404-414 (2003).
29. Zitron E, Karle CA, Wendt-Nordahl G, Kathöfer S, Zhang W., Thomas D, Weretka S, Kiehn J. Bertosamil blocks HERG potassium channels in their open and inactivated states. Br. J. Pharmacol., 137, 221-228 (2002).
30. Kiehn J, Thomas D, Karle C.A., Schöls W, Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch. Pharmacol., 359, 212-219 (1999).
31. Milnes JT, Crociani O, Arcangeli A., Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fuvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol., 139, 887-898 (2003).
32. Jiang M, Dun W, Fan J.S., Tseng GN. Use-dependent 'agonist' effect of azimilide on the HERG channel. J. Pharmacol. Exp. Ther., 291, 1324-1336 (1999).
33. Walker BD, Singleton CB, Tie H, Bursill J.A., Wyse KR, Valenzuela SM, Breit SN, Campbell TJ. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc. Res., 48, 44-58 (2000).
34. Mitcheson JS, Chen J, Lin M., Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A., 97, 12329-12333 (2000).
35. Tomita T, Yasui-Furukori N, Nakagami T., Tsuchimine S, Ishioka M, Kaneda A., Nakamura K, Kaneko S. Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Ther. Drug Monit., 36, 480-485 (2014).
36. Neugebauer G, Akpan W, von Möllendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol., 10 (Suppl. 11), S85-S88 (1987).
37. Tomlinson B, Prichard BN, Graham B.R., Walden RJ. Clinical pharmacology of carvedilol. Clin. Investig., 70 (Suppl. 1), S27-S36 (1992).
38. Hancox JC, Mitcheson JS. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fuoxetine: a case-study in cardiac safety pharmacology. Br. J. Pharmacol., 149, 457-459 (2006).
39. +channel block and disruption of protein trafficking by fuoxetine and nor-fuoxetine. Br. J. Pharmacol., 149, 481-489 (2006).
40. Flugelman MY, Pollack S, Hammerman H., Riss E, Barzilai D. Congenital prolongation of Q-T interval: a family study of three generations. Cardiology, 69, 170-174 (1982).
41. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, Lüderitz B, Rao ML. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit., 23, 435-440 (2001).